SCHEMBL5002869

SCHEMBL5002869

CCCCCCc1ncccc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 1/20 0.50
GABRD O14764 1/20 0.50
GABRA1 P14867 1/20 0.50
GABRB1 P18505 1/20 0.50
GABRG2 P18507 1/20 0.50
GABRB3 P28472 1/20 0.50
GABRA5 P31644 1/20 0.50
GABRA3 P34903 1/20 0.50
GABRA2 P47869 1/20 0.50
GABRB2 P47870 1/20 0.50
GABRA4 P48169 1/20 0.50
GABRE P78334 1/20 0.50
GABRA6 Q16445 1/20 0.50
GABRG1 Q8N1C3 1/20 0.50
GABRG3 Q99928 1/20 0.50
GABRQ Q9UN88 1/20 0.50
PTPN1 P18031 1/20 0.48
KDM4E B2RXH2 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
PLK1 P53350 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29398777 1.00 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4625244 1.00 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5709741 1.00 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5002408 1.00 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL135492 1.00 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4998460 1.00 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL9500202 1.00 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7386044 0.98 GABRP (0.51) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4005286 0.94 GABRP (0.56) GABRPGABRDGABRA1GABRB1GABRG2
Lactic Acid SCHEMBL3485958 0.92 GABRP (0.44) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109379887-A Topical compositions based on carnosine-magnesium complexes 完胜股份有限公司 2019-02-22 CN claimed
CN-107022301-A A kind of low-surface-energy ANTI-FOULING PAINT FOR FISHING NET 巢湖市荷花渔网有限公司 2017-08-08 CN claimed
US-20040147491-A1 Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide NIADYNE, INC. 2004-07-29 US claimed
US-20020041854-A1 Cosmetic compositions in powder form comprising a binder, and make-up and cosmetic care methods L'OREAL S.A. (FR) 2002-04-11 US claimed
US-20020034480-A1 Make-up compositions comprising a binder phase, and make-up methods L'OREAL, S.A. (FR) 2002-03-21 US claimed
US-20010033848-A1 Adjustment of cellular nicotinamide-adenine dinucleotide NIADYNE, INC. 2001-10-25 US claimed
EP-1143954-A2 USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS University of Kentucky Research Foundation (US) 2001-10-17 EP claimed
WO-2000032179-A2 USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2000-06-08 WO claimed
EP-3160438-B9 MINOXIDIL-CONTAINING HAIR GROWTH COMPOSITION JOHNSON & JOHNSON CONSUMER INC (US) 2024-07-17 EP disclosed
EP-3160438-B1 MINOXIDIL-CONTAINING HAIR GROWTH COMPOSITION JOHNSON & JOHNSON CONSUMER INC (US) 2024-02-28 EP disclosed
CN-108472511-B Hair growth compositions and methods 强生消费者公司 2023-07-07 CN disclosed
US-11666520-B2 Hair growth composition and method JOHNSON & JOHNSON CONSUMER INC. (US) 2023-06-06 US disclosed
US-11185487-B2 Hair growth composition and method JOHNSON & JOHNSON CONSUMER INC. (US) 2021-11-30 US disclosed
US-11039996-B2 Hair growth composition and method JOHNSON & JOHNSON CONSUMER INC. (US) 2021-06-22 US disclosed
US-20020034480-A1 Make-up compositions comprising a binder phase, and make-up methods L'OREAL, S.A. (FR) 2002-03-21 US disclosed
US-6337065-B1 FOR THERAPY OF DISORDERS SUCH AS SUNBURN AND OTHER SKIN DETERIORATION THAT RESULTS FROM DNA DAMAGE IN SKIN CELLS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2002-01-08 US disclosed
US-20010033848-A1 Adjustment of cellular nicotinamide-adenine dinucleotide NIADYNE, INC. 2001-10-25 US disclosed
EP-1143954-A2 USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS University of Kentucky Research Foundation (US) 2001-10-17 EP disclosed
WO-2000032179-A2 USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2000-06-08 WO disclosed
US-4795638-A RUBEFACIENT, PLANT EXTRACT, POLYSILOXANE L'OREAL (FR) 1989-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020034480-A1 Make-up compositions comprising a binder phase, and make-up methods TTR, GRN, MB GABRP 683/4885GABRD 1174/4885GABRA1 1232/4885
US-11666520-B2 Hair growth composition and method LDHB, LDHA, SLC25A20 GABRP 4555/4885GABRD 4611/4885GABRA1 4700/4885
US-11185487-B2 Hair growth composition and method COL14A1, HDGF, PCNA GABRP 4633/4885GABRD 4728/4885GABRA1 4816/4885
US-20040147491-A1 Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide NQO1, NNT, NAMPT GABRP 4421/4885GABRD 4578/4885GABRA1 4746/4885
US-20010033848-A1 Adjustment of cellular nicotinamide-adenine dinucleotide NQO1, NNT, NAMPT GABRP 3903/4885GABRD 4457/4885GABRA1 4670/4885
US-20020041854-A1 Cosmetic compositions in powder form comprising a binder, and make-up and cosmetic care methods CUTA, LAGE3, MITF GABRP 1824/4885GABRD 2044/4885GABRA1 1581/4885
US-11039996-B2 Hair growth composition and method CYP21A2, ADH1C, DHCR7 GABRP 4064/4885GABRD 3968/4885GABRA1 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.